Differentiation pathways in carcinogenesis and in chemo- and radioresistance

Janíková, Mária; Škarda, Jozef

doi:10.4149/neo_2012_002

Cited by 26 publications

(22 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Previous studies from our lab and others have clarified multiple mechanisms underlying tumor radioresistance in ESCC. 5, 6, 7, 8, 9, 10 However, these studies paid attention only to tumor cells.…”

Section: Discussionmentioning

confidence: 97%

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Five-year survival rate of esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy is <20%. Our study aimed to investigate whether cancer-associated fibroblasts (CAFs), one major component of tumor microenvironment, were involved in tumor radioresistance in ESCC. By use of human chemokine/cytokine array, human chemokine CXCL1 was found to be highly expressed in CAFs compared with that in matched normal fibroblasts. Inhibition of CXCL1 expression in CAFs significantly reversed CAF-conferred radioresistance in vitro and in vivo. CAF-secreted CXCL1 inhibited the expression of reactive oxygen species (ROS)-scavenging enzyme superoxide dismutase 1, leading to increased ROS accumulation following radiation, by which DNA damage repair was enhanced and the radioresistance was mediated. CAF-secreted CXCL1 mediated the radioresistance also by activation of Mek/Erk pathway. The cross talk of CAFs and ESCC cells induced CXCL1 expression in an autocrine/paracrine signaling loop, which further enhanced tumor radioresistance. Together, our study highlighted CAF-secreted CXCL1 as an attractive target to reverse tumor radioresistance and can be used as an independent prognostic factor of ESCC patients treated with chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 97%

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For example, they contain a high level of ATP-binding cassette (ABC) proteins that acts as drug efflux pumps to actively remove harmful drugs out of cells, rendering them ineffective. Furthermore, CSCs contain multiple enzymes capable of drug metabolism and several DNA repair and anti-apoptotic proteins [131]. Several lines of evidence indicate that Hh signaling plays a key role in the regulation of cancer stem cells (CSCs).…”

Section: Therapeutic Application Of Hedgehog Inhibitionmentioning

confidence: 99%

Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication

Gonnissen

Isebaert

Haustermans

2013

IJMS

View full text Add to dashboard Cite

Activation of Hedgehog (Hh) signaling is implicated in the development and progression of several tumor types, including prostate cancer, which is still the most common non-skin malignancy and the third leading cause of cancer-related mortality in men in industrialized countries worldwide. Several studies have indicated that the Hh pathway plays a crucial role in the development as well as in the progression of this disease to more aggressive and even therapy-resistant disease states. Moreover, preclinical data have shown that inhibition of Hh signaling has the potential to reduce prostate cancer invasiveness and metastatic potential. Clinical trials investigating the benefit of Hh inhibitors in patients with prostate cancer have recently been initiated. However, acquired drug resistance has already been observed in other tumor types after long-term Hh inhibition. Therefore, combining Hh inhibitors with ionizing radiation, chemotherapy or other molecular targeted agents could represent an alternative therapeutic strategy. In this review, we will highlight the role of Hh signaling in the development and progression of prostate cancer and summarize the different therapeutic applications of Hedgehog inhibition.

show abstract

“…More importantly, there is a growing body of evidence suggesting that CSCs contribute to radioresistance [42••–44]. The relatively higher radioresistance of CSCs has been attributed to different intrinsic and extrinsic factors.…”

Section: Notch-1 and Radiosensitizationmentioning

confidence: 99%

Honokiol as a Radiosensitizing Agent for Colorectal Cancers

Subramaniam

Zhang

et al. 2013

Curr Colorectal Cancer Rep

View full text Add to dashboard Cite

Radioresistance is a frustrating obstacle for patients with colorectal cancers (CRCs) undergoing radiotherapy. There is an urgent need to find an effective agent to increase the sensitivity of CRCs to radiation. Honokiol, an active compound purified from Magnolia, was found to radiosensitize colorectal cancer cells both in vitro and in vivo. However, the mechanisms control important signaling that enhances radiosensitivity is currently unknown. In this study, we have reviewed important signaling pathways that are closely related to radiosensitization, such as cell cycle arrest, tumor angiogenesis, JAK/STAT3 signaling pathway and Mismatch repair. Studies show that honokiol can interfere with these pathways at different levels. With overall analysis, it may bring light on finding the possible mechanism by which honokiol acts as a radiosensitizing agent for CRCs.

show abstract

Differentiation pathways in carcinogenesis and in chemo- and radioresistance

Cited by 26 publications

References 118 publications

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication

Honokiol as a Radiosensitizing Agent for Colorectal Cancers

Contact Info

Product

Resources

About